Taking On Debt And Executing A Public Offering During COVID-19
Source: Life Science Leader
Rob Wright, chief editor of Life Science Leader, recently conducted a virtual roundtable with three CEOs of publicly traded biopharmaceutical companies (view full video here). In this segment, Bill Newell, CEO of Sutro Biopharma (NASDAQ: STRO), answers why his company took on $25 million in debt and closed a $98 million public offering despite the U.S. entering a pandemic driven recession.
This website uses cookies to ensure you get the best experience on our website. Learn more